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Phospholipases are a complex and important group of enzymes widespread in nature, that play crucial roles in diverse biochemical
processes and are classiﬁed as A1,A 2, C, and D. Phospholipases A1 and A2 activities have been linked to pathogenesis in various
microorganisms, and particularly in pathogenic protozoa they have been implicated in cell invasion. Kinetoplastids are a group of
ﬂagellated protozoa, including extra- and intracellular parasites that cause severe disease in humans and animals. In the present
paper, we will mainly focus on the three most important kinetoplastid human pathogens, Trypanosoma brucei, Trypanosoma
cruzi,a n dLeishmania spp., giving a perspective of the research done up to now regarding biochemical, biological, and molecular
characteristics of Phospholipases A1 and A2 and their contribution to pathogenesis.
1.Introduction
Kinetoplastids are a group of ﬂagellated protozoans distin-
guished by the presence, in their single large mitochondrion,
of a DNA-containing region known as kinetoplast. These
unicellular organisms have a similar genomic organization
and cellular structures and undergo morphological changes
during their life cycles, being transmitted by diﬀerent insect
vectors. The members of this group include extra- and
intracellular parasites that cause severe diseases in humans
and animals, as well as various free-living forms. Herein,
we will mainly focus on the three most important human
pathogens Trypanosoma brucei, Trypanosoma cruzi, and
Leishmania spp.
T. brucei and its subspecies are extracellular parasites
transmitted by tsetse ﬂies and responsible of human African
trypanosomiasis (HAT), also known as African sleeping
sickness, and Nagana in cattle. The life cycle of African
trypanosomes is complex and represented by extracellular
stages found in blood, lymph, and spinal ﬂuid in the mam-
mal [1]. The disease threatens over 70 million people and
uncounted numbers of cattle in 36 countries of sub-Saharan
Africa, having a devastating impact in human health and
economy in aﬀected areas [2]. HAT symptoms occur in two
stages; in the ﬁrst, haemolymphatic phase, parasite invasion
of the circulatory and lymphatic systems is associated with
severe swelling of lymph nodes. If untreated, the disease
overcomes the host’s defences and can cause more extensive
damage. The second stage, neurological phase, begins when
the parasite invades the central nervous system by passing
throughtheblood-brainbarrier;withouttreatment,itisfatal
and the damage caused can be irreversible [1].
T. cruzi in contrast, is an intracellular parasite that
invades all types of nucleated cells in the mammalian host.
This protozoa, transmitted through the faeces of bloodsuck-
ing insects of the Triatominae family, enters the mammalian
host via damage to the skin and causes Chagas disease in
humans, a chronic inﬂammatory condition characterized by
cardiomyopathy, megacolon, and mega-esophagus [3]. The
disease is prevalent throughout America and according to
WHO estimations, 25 million people are at risk and 10
million are infected worldwide [4]. Chemotherapy against
Chagas disease is limited and unsatisfactory. The two
available drugs, nifurtimox and beznidazole, are capable of
curing at least 50% of recent infections and both produced
side eﬀects [5].
The genus Leishmania comprises 20 species of intracellu-
lar protozoan that are transmitted by phlebotomine sandﬂies
and infect speciﬁcally cells of the mononuclear phagocyte
system in mammals. These parasites cause various diseases2 Enzyme Research
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Figure 1: Hydrolysis of phospholipids by phospholipases. Arrows
indicate the sites of attack for hydrolytic cleavage of phospholipases
type A1,A 2, C, and D. The main products generated by their action
are also shown. R1/R2: free fatty acids in sn-1 or sn-2 positions; X:
choline, ethanolamine, serine, inositol, and so forth.
ranging from self-healing cutaneous leishmaniasis, mucocu-
taneous leishmaniasis, with partial or total destruction of
the mucous membranes, to severe and lethal (if untreated)
visceralleishmaniasis,alsoknownaskala-azar.Leishmaniasis
iswidespreadinSouthernEurope,Africa,Asia,andAmerica,
threatening 350 million people in 88 countries around the
world and represents an important global health problem
that results in a signiﬁcant economic burden [6].
One of the major components of biomembranes present
inalllivingorganismarephospholipids(PL),whichformthe
lipid bilayer and serve as hydrophobic anchors of membrane
proteins. These compounds can be enzymatically modiﬁed
by the action of phospholipases (PLAs), with generation of
bioactive lipid molecules that can act as second messengers
and also modulate the immune response [7–9]. Moreover,
PLAs have been considered virulence factors for many
pathogenic bacteria like Escherichia coli, Helicobacter pylori,
Neisseria spp. Yersinia spp.,a n ds of o r t h[ 10–14].
PLAs are a complex and important group of enzymes,
widespread in nature, that play crucial roles in diverse
biochemical processes and are classiﬁed as A1,A 2,C ,a n d
D, depending on the site of hydrolysis [15]. These enzymes
cleave cell membrane and intracellular PL releasing a variety
of products such as lysophospholipids (LPL), free fatty acids
(FFA), diacylglycerols (DG), choline phosphate, phospho-
inositides and phosphatidic acid, among others (Figure 1).
Phospholipase A1 (PLA1) (EC 3.1.1.32) speciﬁcally
hydrolyses acyl groups from PL at the sn-1 position, produc-
ing FFA and LPL (Figure 1)[ 15]. PLA1 activities have been
detectedinvariouscelltypesandtissuesfromawiderangeof
organisms by measuring hydrolysis of phosphatidylcholine
(PC) to lysophosphatidylcholine (LPC) [15]. But despite
their apparent ubiquity and diversity, up to now a limited
number of PLA1s have been cloned and characterized [16–
18]. Increasing evidence indicates that some PLA1sa r e
capable of generating bioactive lipids, a role traditionally
assigned to PLAs A2, C, and D, though the biological
relevance of this particular PLA deserves to be deeply studied
[16, 19, 20].
At present time, nine PLA1 molecules are known in
mammals, being six extracellular and three intracellular
enzymes, sharing no sequence homology between them and
probably having distinct functions [7]. The extracellular
PLA1s belong to the pancreatic lipase gene family, that is
conserved in an extensive range of organisms from insects
to mammals and have been biochemically characterized
and classiﬁed, according to their substrate speciﬁcities,
structures, expression patterns, and possible functions [7].
Some PLA1s have a broad substrate speciﬁcity and might
also have triacylglycerol lipase activity (EC 3.1.1.3) [21].
Others, such as phosphatidylserine-speciﬁc PLA1sf r o m
rat platelets and membrane-associated phosphatidic acid
PLA1α and PLA1β, show strict substrate speciﬁcity [20]. The
latter PLA1sh a v es p e c i ﬁ cr o l e si np r o d u c i n gb i o a c t i v eL P L ,
lysophosphatidylserine, and lysophosphatidic acid [7].
Phospholipases A2 (EC 3.1.1.4), in contrast to PLA1,a r e
the most widely studied. Great advances in understanding
the structure and function of the superfamily of Phospho-
lipase A2 (PLA2) has occurred in the last decades [9, 22–
25]. This superfamily includes ﬁfteen groups, comprising
four main types including secreted PLA2 (sPLA2), cytosolic
PLA2 (cPLA2), Ca2+-independent PLA2 (iPLA2), and platelet
activating factor acetyl hydrolase/oxidized lipid lipoprotein
associated PLA2 (LpPLA2)[ 9]. The classiﬁcation is based
upon the following characteristics: source, secreted, or
cytosolic, availability of structural information, molecular
weight, cofactors, and inhibitor speciﬁcity [9]. sPLA2sh a v ea
low molecular weight (∼14kDa) and contain a large number
of disulphide bridges, consistent with their extracellular
environment, and require millimolar concentrations of Ca2+
for optimum catalytic activity [9]. cPLA2sh a v eah i g h
molecular weight (∼85kDa) and preferentially hydrolyze PL
containing arachidonic acid, therefore playing a key role in
the biosynthesis of eicosanoids, precursors of prostaglandins
and thromboxane [26]. Full activation of these enzymes
requires Ca2+ binding to an N-terminal C2 domain and
phosphorylation on serine residues [23]. iPLA2sh a v ea
high molecular weight (85–88KDa), contain seven to eight
ankyrin repeats, one of the most common sequence motif,
and the consensus lipase motif GXSXG, being detected
mainly in human tissues [27].
Considering the important and various roles that PLAs
possess,inthepresentreview,wewillsummarizetheresearch
done to date in Trypanosomes regarding biochemical, bio-
logical, and molecular characteristics of PLAs and their
contribution to pathogenesis.
2.BiochemicalandBiologicalCharacteristicsof
the Trypanosomatids Phospholipases A
2.1. Phospholipase A1. In 1978, Tizard et al. described the
presence of a haemolytic activity in T. congolense, due to
the FFA generated by the action of PLA on endogenous PC,
meanwhileinthenonpathogenicT. lewisi,noFF AgenerationEnzyme Research 3
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Figure 2: Multiple sequence alignment of trypanosome PLA1. Alignment of the protein sequences of cloned T. brucei, T. cruzi, and
L. braziliensis PLA1 and T. congolense and T. vivax putatives PLA1 was performed with NTI 10 Software (Invitrogen) using the Clustal
W algorithm. The lipase consensus pattern is underlined. Letters indicate: identical (red), conserved (blue), similar (green), weakly
similar (grey), and nonsimilar (black) amino acids. Leishmania braziliensis PLA1 (TriTrypDB LbrM31 V2.2750), Trypanosoma brucei
PLA1 (TriTrypDB Tb.927.1.4830), Trypanosoma congolense putative PLA1 (TriTrypDB TcIL3000.1.2010), Trypanosoma vivax putative PLA1
(TriTrypDB TvY486 0102170), and Trypanosoma cruzi PLA1 (TriTrypDB Tc00.1047053510679.100).
was observed and therefore, nonhaemolytic activity was
detected [28]. Further, it was determined in four diﬀerent
species of African trypanosomes that Ca2+-independent
PLA1 was the predominant PC-degrading activity. The
levels of PLA1 varied widely, with very high activity in
the pathogenic T. brucei and relatively low activity in the
nonpathogenic T. lewisi species [29]. Other authors found
that T. brucei bloodstream forms possess high levels of
PLA1 activity, whereas in the procyclic culture forms PLA1
speciﬁc activity was only 15% of that of bloodstream forms,
suggesting an important physiological role for the enzyme in
the mammalian stage [30]. Bloodstream trypomastigotes are
covered with a dense layer of Variant Surface Glycoprotein
(VSG), which protects the parasite from lysis by host
complement via the alternative pathway [31]. It has been
suggested that the high activity of PLA1 in these forms, may
play a role in the acquisition of fatty acids for synthesis of
the VSG and also provide a source of myristate that can be
employed for remodelling the lipid anchor of the VSG [32].
PLA1 was puriﬁed from T. brucei bloodstream forms,
where the major portion was found as a soluble activity
in the cytosol and the minor as a particle-bound activity
associated with lysosomal markers. Both enzymes had
o p t i m a la c t i v i t ya ta c i dp Ha n dw e r ea c t i v a t e db yT r i t o nX -
100 [30]. Although cultured procyclic trypomastigotes also
possess PLA1 activity, the levels were signiﬁcantly reduced
compared to bloodstream forms, due to a decrease in soluble
PLA, similar levels of lysosomal activity were present in
both stages [30]. Other authors reported that PLA1 activity
eluted together with a lysophospholipase activity (LPLA)4 Enzyme Research
(EC:.3.1.1.5), suggesting that a single enzyme displays both
activities [33].
T. brucei PLA1 (TbPLA1) has been recently cloned and
expressed as recombinant protein [34]. This intracellular
enzyme is localized in the cytosol and has optimal activity
at neutral pH and a predicted size of 34.8kDa. TbPLA1
deacylates choline-containing PLs, with greater eﬃciency
than those containing ethanolamine, inositol, serine, or just
phosphorous at the sn-3 position [34]. The enzyme also
displayed LPLA activity towards LPC, as previously reported
[33].
As regards T. cruzi, we previously determined that when
e p i m a s t i g o t e sw e r eg r o w na t2 8 ◦C and then transferred to
37◦C, a fatty acid exchange occurs between PL and neutral
lipids [35]. This mechanism of membrane lipid adaptation
suggested for the ﬁrst time the action of PLA activity as
part of a deacylation-reacylation cycle in T. cruzi [35].
Other authors reported membrane PLA1 and PLA2 activities
in epimastigotes, but acting only on anionic PL such as
inositolphospholipids and inositolphosphoceramides [36].
WefurtherdeterminedthepresenceofaPC-PLA1-degrading
activity in all parasite stages, being up to 20-fold higher in
the infective amastigotes and trypomastigotes than in the
noninfective epimastigotes, as occurs in T. brucei, where the
mammalian stages possess the highest levels of PLA1 activity
[30, 37]. Interestingly, in both infective stages membrane-
bound PLA1 activity was remarkably higher than those
detected in organelle bound or soluble fractions [38]. This
localization does not appear to have a similar counterpart
in T. brucei, where the major proportion of activity (more
than 90% of the total) corresponds to a soluble cytosolic
fraction [30]. In T. cruzi epimastigotes, in contrast, the
enzyme was only detected in lysosomes [37]. It is remarkable
that only infective stages secreted PLA1 to the extracellular
media [38], similarly to other enzymes that participate in
T. cruzi endocytic pathway, such as cruzipain and trans-
sialidase [39–42]. We puriﬁed T. cruzi PLA1 (TcPLA1)f r o m
epimastigote and amastigotes, obtaining in both cases a
unique band of ∼38kDa. These enzymes proved to be
independent of the bivalent cations Ca2+,M n 2+,a n dM g 2+,
had an optimum acidic pH, and were activated by Triton
X-100. The biochemical characteristics of TcPLA1 activities
were similar to those reported for TbPLA1 and other PLA1s
from mammalians [43, 44]. As previously demonstrated in
T. brucei we also determined the presence of LPLA activity in
autolysing parasites [17, 33, 45].
As concerns secreted TcPLA1, we determined during
metacyclogenesis, process in which epimastigotes diﬀerenti-
ate into the infective metacyclic trypomastigotes, an increase
in secreted enzyme activity simultaneously with the appear-
ance of metacyclic forms, as expected [38]. Accordingly, it
has been reported that membrane PLA1,A 2, and C, may
act in remodelling reactions needed for plasma membrane
transformation during T. cruzi diﬀerentiation; these enzyme
activities may be acting in remodelling reactions leading to
the anchor of the mature glycoproteins of T. cruzi [46].
In the case of Leishmania spp., preliminary results of
our laboratory have also demonstrated in L. braziliensis
promastigotes a PLA1 activity hydrolyzing PC. Moreover, we
detectedbyImmunoblottwobandsof∼37and41kDa,using
polyclonalantibodiesagainstbothTcPLA1 andTbPLA1 [47].
These antibodies were obtained in our laboratory, since no
commercial antibodies against any PLA1 were available until
this year [48].
2.2. Phospholipase A2. The eukaryotic PLA2 were the ﬁrst
of the PLAs to be recognized. The pancreatic PLA2 has
been known to degrade PC since 1878, and at the turn of
the century cobra venom was shown by Keyes in 1902 to
have haemolytic activity directed towards the membranes
of erythrocytes [49]. Secreted and membrane-bound PLA2
activity has been described in Bacteria, Fungi and Protozoa
[50–54], but in the case of Trypanosomes just a few reports
are available.
PLA2 was isolated from T. congolense; the enzyme
appeared to exist in a dimeric form with subunit molec-
ular weights of 16.5 and 18kDa, had optimum pH of
6.8, and showed speciﬁcity for 1,2,dimyristoyl-sn-PC and
1,2,dioleoyl-sn-PC [55]. Inhibition studies implicated a thiol
group at the catalytic site of the enzyme, which was stable to
heat treatment and possessed haemolytic and anticoagulat-
ing properties [55].
In T. brucei bloodstream forms, other authors reported
aP L A 2 activity that could be stimulated by Ca2+ or by the
amphiphilic peptide melittin, and that was responsible of
the release of arachidonic acid, a prostaglandins precursor,
being a pivotal enzyme in the control of Ca2+ inﬂux [56,
57]. In addition, it was demonstrated in T. brucei procyclic
forms, that the arachidonic acid generated endogenously
could induce both Ca2+ entry and Ca2+ release from the
intracellular compartments acidocalcisomes, suggesting that
PLA2 activity participates in T. brucei signalling events [58].
On the other hand, in L. donovani promastigotes and T.
cruzi amastigotes, these authors found that arachidonic acid
only induced Ca2+ entry, possibly due to low generation of
arachidonic acid or to the low amount of releasable Ca2+ in
the acidocalcisomes of these cells [58].
Previous reports in T. cruzi suggested that PLA2
could mediate the association between the parasite and
macrophages, but the authors did not clearly establish the
source of the enzyme [59]. In epimastigotes, it has been
described a haemolytic activity that destabilize in vitro red
blood cells membranes and that could be attributed to PLA2
activity [60]. However under our experimental conditions
using zwitterionic PL such as PC or PE as substrates, no
secreted PLA2 was detected in the supernatants of living
epimastigotes [38]. In this concern, other authors have
described in this protozoa a membrane-bound PLA2 activity
acting only on anionic PL such as inositolphospholipids and
inositolphosphoceramides [36].
PLA2 degrading activities have been also reported in L.
major, and they could be involved in the biosynthesis of
lipophosphoglycan, the main macromolecule on the surface
of the procyclic promastigote [61]. Other authors showed
thatparasitepretreatmentwithalowdoseofpachymatismin,
a glycoprotein extracted from a marine sponge, increased
PLA2 activity, however macrophage invasion was partially
inhibited [62].Enzyme Research 5
Table 1: Phospholipase A2 putative genes found in TriTrypDB.
Gene Organism Product Syntenic Comments
LbrM34 V2.2930 L. braziliensis phospholipase A2-like protein, putative yes no
LinJ35 V3.3070 L. infantum phospholipase A2-like protein, putative yes no
LmjF35.3020 L. major phospholipase A2-like protein, putative yes no
LmxM34.3020 L. mexicana
mexicana phospholipase A2-like protein, putative yes no
Tbg972.9.7760 T. brucei
gambiense phospholipase A2-like protein, putative yes no
TclL3000.0.00740 T. congolense product unspeciﬁed no no
Tc00.1047053510743.60
T. cruzi CL
Brener
Esmeraldo-like
phospholipase A2-like protein, putative yes no
Tc00.1047053510659.250
T. cruzi CL
Brener Non-
Esmeraldo-like
phospholipase A2-like protein, putative yes no
TvY486 0906130 T. vivax phospholipase A2-like protein, putative yes no
On the other hand, in L. amazonensis the modiﬁcation of
PLcomposition of infected macrophageshasbeen described,
with increasing levels of LPC, an eﬀect that may reﬂect
indirectly, the action of an endogenous/parasite PLA2 on the
macrophage [63]. Furthermore, other studies showed PLA2
activity in supernatants and lysates of L. (L.) amazonensis
promastigotes and suggested that this enzyme may be a
progression factor for cutaneous leishmaniasis [64].
In summary, there are increasing evidences of the
presence and possible roles of PLA2 in the pathogenic
Trypanosomes, so far however, these enzymes have not been
puriﬁed or characterized in deep.
3. Phospholipases A of Trypanosomatids
andPathogenesis
PLA activity has been linked to pathogenesis in various
microorganisms such as Escherichia coli, Yersinia spp, Heli-
cobacter pylori, Neisseria spp, Legionella spp., and Campy-
lobacter spp., which cause diﬀerent disease syndromes;
however, the exact mechanism of the PLA action has not
been deﬁnitively determined [10–14, 65, 66]. PLA toxicity
has been associated to cytolytic activity resulting from the
accumulation of membrane-destabilizing products or by
the extensive destruction of membrane phospholipids [10].
In pathogenic protozoa PLAs have been implicated in cell
invasion [54, 67, 68]; in Toxoplasma gondii it has been
described that PLA2 inhibition protected human monocytic
cells from parasite invasion [53]; in Entamoeba histolytica,
PLA2 is one of the several factors related to virulence [54]
and in Cryptosporidium parvum the use of PLA2 inhibitors
as well as speciﬁc anti PLA2 antibodies signiﬁcantly reduced
invasion of human enterocytes [68].
The role of PLA1 in the pathogenesis of African try-
panosomiasis has been intensively studied [29, 45, 69, 70].
Hambrey et al. described in the tissue ﬂuids of T. brucei
infectedrabbitslargeamountsofPLA1 activitythatincreased
with parasite burden, whereas in blood plasma this activity
was also detected, but at a considerably lower level [70]. The
enzyme seemed to be of trypanosomal origin, being either
secreted by living parasites or released from dying organisms
[70]. In intravascular locations PLA1 could contribute to
the pathology of trypanosomiasis by causing cell membrane
damage and could account for some or all of the connective
tissue cell destruction, which is a prominent feature of
infections with T. brucei [71].
The high level of PLA1 found in T. congolense and T.
brucei, in comparison to other pathogens like Escherichia coli
(1000 times fold higher) [33], and its relatively low level
in the nonpathogenic rat trypanosome T. lewisi,s u g g e s t e d
the importance of the enzyme in the pathology of African
trypanosomiasis [28, 29, 45, 69, 72]. Given that T. lewisi
and T. congolense are restricted almost entirely to the blood
stream of the host, whereas T. brucei develops mainly in the
connectivetissues[71],itwassuggestedthatPLA1 could help
the latter to penetrate blood vessels endothelium and other
barriers hindering and contributing to tissue damage [29].
In the pathogenic T. brucei and T. congolense it has been
determined that PLA1 activity increased greatly during the
autolytic process and large quantities of FFA were accumu-
lated, whereas the non pathogenic T. lewisi failed to increase
the enzyme activity even on prolonged autolysis [69]. PLA1
yields FFA and LPC, which is then further degraded by
the LPLA to yield more FFA and glycerophosphorylcholine.
FFA are cytotoxic and haemolytic as a result of their
detergent-like properties [73], and they could account for
the immunosuppression and the structural disturbances in
lymphoid organs observed in African trypanosomiases [69].
Theseobservationsdeservetobeupdatedanddeeplystudied.
The ﬁrst evidences related to phospholipid degrading
enzymes in T. cruzi, was associated to the inﬂammatory
responses that appear surrounding degenerating amastigote
nests in various tissues of Chagas’ disease patients [74].
This ﬁnding strongly suggested that autolytic processes
generate factors, possibly PL-breakdown products, which6 Enzyme Research
cause inﬂammation [11]. In this regard, it was demonstrated
that FFA and LPL released from killed trypomastigotes
have toxic eﬀects on culture cells [12] .T h e s ef a c t sa r ei n
agreement with the pathogenic mechanism proposed for
African trypanosomiasis [29, 69]. Accordingly, we deter-
minedinallT.cruzistagestherapidandextensivebreakdown
of endogenous PL in autolysing parasites [37]. A major
increase in FFA was observed, signiﬁcantly higher than the
generation of LPC, indicating not only the presence of PLA1
activity but also LPLA activity [37]. We also found that
living T. cruzi infective stages were able to hydrolyze LPC,
conﬁrming the presence of a LPLA activity (Belaunzar´ an
et al. unpublished observations). It is well known that
LPC is potentially toxic for the cells [75, 76] though this
activity would thereby contribute signiﬁcantly to the parasite
self-protection against lysocompounds. Similarly, in living
T. brucei it has been demonstrated that PLA1 is active
against LPL [77]. Other authors reported that bloodstream
forms can acquire substantial amounts of exogenous LPL
through a pathway consisting of three enzymes associated
with the plasma membrane: PLA1, acyl-COA ligase, and LPC
acylCOA-acyl transferase [32]. These cytotoxic compounds
can change the ionic permeability of the plasma membrane,
thoughtheyarerapidlymetabolizedtoensuretolerablelevels
in the cell. Thus a membrane-bound PLA1 would protect T.
brucei against the high levels of plasma LPC [32].
In T. cruzi, we already showed the involvement of PLA1
in the early events of parasite-host cell interaction preced-
ing parasite invasion. We demonstrated that either intact
infective parasites or puriﬁed PLA1 signiﬁcantly modiﬁed
the host cell lipid proﬁle with generation of second lipid
messengers (DG, FFA, and LPC) and concomitant protein
kinase C activation [38], an enzyme that has been implicated
in the upregulation of T. cruzi invasion [78].
With respect to Leishmania spp., it has been observed
that LPC, which is scare in the macrophage, increased
signiﬁcantly after infection with L. amazonensis [63]. As LPC
and arachidonic acid are the products of PC cleavage by
PLA2, the increase in the levels of LPC may suggest the
action of the enzyme on the macrophage PC, producing
prostaglandin E2 [63]. In this regard, it has been shown
that this lipid mediator is increased after 1-2 hours of
infection with L. donovani and can exacerbate the infection
[79]. Nevertheless, whether the LPC generation was due
to parasite PLA2 or to the activation of macrophage PLA2
remains unclear [63]. It is possible that the LPC could also
be generated by a PLA1 activity, similarly to that we detected
in L. braziliensis [47].
4. Bioinformatic Analysisof
the Trypanosomatid Genomes for
Phospholipases A
The publication of the genomes of the kinetoplastid parasites
T. brucei [80], T. cruzi [81], Leishmania spp.[ 82], and
other related organisms, allowed the scientiﬁc community to
perform comparative analyses giving insight into the evolu-
tionary similarities/diﬀerences among trypanosomatids.
T. brucei PLA1 (Tb.927.1.4830) has been cloned and
characterized and the analyses of its protein sequence
indicated that this enzyme is not homologous to neutral
lipases [34]. The only similarity to them was in the amino
acidic sequence that contains a lipase consensus pattern
harbouringaconservedGXSXGmotif,amarkeroftheserine
hydrolase superfamily [34]. In these enzymes, the catalytic
triad is typically constituted by a base residue (Histidine),
an acid (Aspartic), and a nucleophile (Serine), belonging to
the latter to the GXSXG motif. No eukaryotic homologues
of TbPLA1 were found in T. cruzi and Leishmania spp., but
orthologues of this enzyme were identiﬁed in T. congolense
(TcIL3000.1.2010) and T. vivax (TvY486 0102170) [34].
Interestingly, TbPLA1 resembled a putative PLA1 homologue
from Sodalis glossinidius, a proteobacterium endosymbiont
of tsetse ﬂies. These ﬁndings suggested that a T. brucei
ancestor acquired the PLA1 gene through horizontal gene
transfer after/during its adaptation to a parasitic lifestyle in
the insect vector [34].
Regarding T. cruzi, we previously reported the pres-
ence in the T. cruzi data base (http://www.tcruzidb.org/)
of at least sixteen diﬀerent genes encoding putative
lipases and the identiﬁed sequences presented a high
degree of similarity among them (70–80%), may be
haplotype variants [38]. When we further performed a
search in the Kinetoplastid Genomic Resource TriTryDB
(http://tritrypdb.org/tritrypdb/) using only the lipase con-
sensus pattern of TbPLA1 and considering the biochemical
characteristics of T. cruzi PLA1, the number of puta-
tive genes was reduced to eight [38]. One of them
(Tc00.1047053510679.100) was cloned and expressed in E.
coli, being the recombinant enzyme recognized by both
anti-TcPLA1 and anti-TbPLA1 antibodies [48]. The eight
sequences are currently under study in our laboratory, to
elucidate the identity of each of these genes that codify
for T. cruzi PLA1 and to obtain the active recombinant
enzyme.
We extended these analyses to Leishmania spp., searching
in the TriTryDB database for homologues of T. cruzi PLA1
putative genes and have identiﬁed in L. braziliensis, L.
infantum, and L. major, three, nine and eight putative genes
with the conserved lipase motif, respectively. One of the
putative genes from L. braziliensis,L b r M 3 1V2.2750, was
c l o n e da n de x p r e s s e di nE. coli, being the recombinant
protein recognized by both anti-TcPLA1 and anti-TbPLA1
antibodies [47]. At present, we are running assays with the
aim of obtaining and characterizing the active recombinant
enzyme.
The alignment of the protein sequences correspond-
ing to the cloned T. brucei, T. cruzi, and L. brazilien-
sis PLA1 (Tb.927.1.4830, Tc00.1047053510679.100, and
LbrM31 V2.2750, resp.), with the putative PLA1sp r o -
teins of T. congolense and T. vivax, (TcIL3000.1.2010 and
TvY486 0102170), shows that the sequences of T. brucei, T.
congolense, and T. vivax are closely related, whereas T. cruzi
and L. braziliensis only share with all of them the lipase
motif (Figure 2). The fact that T. cruzi and L. braziliensis
PLA1 protein sequences do not share signiﬁcant homologies
with African trypanosomes, particularly with TbPLA1,i si nEnzyme Research 7
agreement with that previously observed by Richmond and
Smith [34].
Although PLA2 activity was detected in T. brucei, T.
congolense, T. cruzi, L. major, and L. amazonensis years ago,
still little is known about the identity of the genes that codify
for them [36, 55, 56, 61, 63, 83]. We have performed a search
in the TriTrypDB database and identiﬁed at least 9 putative
PLA2-like proteins in the diﬀerent Trypanosomes species
(Table 1), but at the moment no PLA2 of trypanosomal
origin has been identiﬁed in the genomes or cloned.
5. Inhibitorsof Trypanosomatid
Phospholipases A
As described above, parasite PLAs participate in diverse
and relevant cellular processes such as membrane remod-
elling, modiﬁcation of membrane permeability, generation
of lipid second messengers and parasite invasion. All these
facts emphasize the interest of these enzymes as potential
chemotherapeutic targets that could contribute to the con-
trol of parasite proliferation and survival.
A number of compounds with potential inhibitory
activity on parasite PLA1 have been investigated. TbPLA1
activity was inhibited by several heavy metals through an
undeﬁned mechanism, being the most potent at lower con-
centrations cadmium and copper. Iron produced partial to
total inhibition depending on the concentrations employed,
whereas moderate inhibition was detected in the presence
of relatively high concentrations of nickel and zinc [34]. As
the active-site residue for TbPLA1 is Serine 131, the active-
siteserinemodiﬁersiPr2P-F(di-isopropylﬂuorophosphate),
PMSF (phenylmethylsulfonyl ﬂuoride), and E-600 (diethyl-
p-nitrophenyl phosphate) were also assayed. Relatively little
inhibition of the enzyme activity was observed but at very
high concentration of inhibitors, suggesting that the catalytic
triad active site of TbPLA1 is buried inside the enzyme and
sheltered by a lid domain, a property shared with other
lipases [34].
Other compounds with potential inhibitory activity on
TcPLA1 were investigated in our laboratory, including the
antimalarialdrugsquinineandchloroquine,theantiarrhyth-
mic drugs amiodarone and chlorpromazine, and the local
anaesthetics dibucaine, procaine, and xylocaine. Among all
of them, only chlorpromazine had an inhibitory eﬀect, but at
concentrations that induce cell toxicity [37].
As previously mentioned, in T. brucei Ca2+ inﬂux can
be regulated by PLA2 [56, 58]. Various inhibitors of this
enzyme such as thioetheramide-PC, manoalide, arachidonyl
triﬂuoromethyl ketone, and aristolochic acid were tested in
this protozoa, being the most eﬀective in blocking Ca2+
inﬂux 3-(4-octadecyl)-benzoylacrylic acid (OBAA), a potent
inhibitor of secreted PLA2 [56]. On the other hand, T. brucei
gambiense and T. brucei brucei PLA2s were inhibited in a
noncompetitive fashion when using organotin compounds
like fatty acid derivatives of dibutyltin dichloride [83]. In the
case of T. cruzi, it has been suggested that quinacrine, which
inhibited erythrocyte lyses, blocked PLA2 activity [60].
Concerning Leishmania spp., up to now, there are no
reports about the use of speciﬁc PLA inhibitors. However,
it has been reported that the lysophospholipid analog (LPA)
miltefosine, aﬀects lipid metabolism in Leishmania donovani
promastigotes, with reduction in PC and enhancement in PE
and LPC, a process in which PLAs could participate among
other enzymes [84]. The usefulness of lipid biosynthesis
inhibitors has gained great interest in the last years to
ﬁght parasitic Trypanosomes [5, 85–88]. These compounds,
initially developed to be antitumor agents, have proved to
be highly eﬀective in the treatment of visceral leishmaniasis
[87, 89, 90]. Although their eﬀectiveness is known, the mode
of action against this parasite is not completely understood
[91]. In T. cruzi, the synergy of the LPAs edelfosine,
ilmofosine, and miltefosine with the ergosterol biosynthesis
inhibitor, ketoconazole, induced alterations in the plasma
membrane, reservosomes, and mitochondrion, indicating
that these organelles are potential targets of these drugs,
probably through interference with lipid metabolism [92].
ConsideringthatPLAsarepresentinboth,trypanosomes
and mammalian host, it will be of relevance to achieve
the knowledge of their three-dimensional structures to
determine the diﬀerences/similarities among them. This
would allow the rational design of speciﬁc inhibitors that
could be employed as potential chemotherapeutic agents in
the diseases caused by kinetoplastid pathogens.
6. Concluding Remarks
In summary, as presented in this paper PLAs of pathogen
trypanosomes mediate a variety of processes in both proto-
zoan and host cell lipid metabolism, being also considered
virulence factors. However, the knowledge of these enzymes
is far from complete, though in the future, continued
biochemical,biological,andstructuralresearchareneededto
obtain a full understanding of the molecular mechanism in
which these enzymes participate. Unravelling the diﬀerences
between parasite and host PLAs may contribute, besides, to
the design of speciﬁc enzyme inhibitors that could be used
in the treatment of the neglected diseases that trypanosomes
cause.
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